Halozyme Therapeutics, Inc. (HALO)
108.64
+0.47
(+0.43%)
USD |
NASDAQ |
Aug 24, 16:00
108.64
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Shareholders Equity (Quarterly) : 143.54M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 143.54M |
| March 31, 2026 | 219.64M |
| December 31, 2025 | 48.81M |
| September 30, 2025 | 503.92M |
| June 30, 2025 | 332.75M |
| March 31, 2025 | 482.27M |
| December 31, 2024 | 363.82M |
| September 30, 2024 | 452.70M |
| June 30, 2024 | 289.42M |
| March 31, 2024 | 177.81M |
| December 31, 2023 | 83.81M |
| September 30, 2023 | 249.18M |
| June 30, 2023 | 151.03M |
| March 31, 2023 | 65.85M |
| December 31, 2022 | 169.80M |
| September 30, 2022 | 96.99M |
| June 30, 2022 | 293.17M |
| March 31, 2022 | 260.26M |
| December 31, 2021 | 196.95M |
| September 30, 2021 | 281.67M |
| June 30, 2021 | 119.75M |
| March 31, 2021 | 67.60M |
| December 31, 2020 | 151.05M |
| September 30, 2020 | 98.99M |
| June 30, 2020 | 105.58M |
| Date | Value |
|---|---|
| March 31, 2020 | 58.04M |
| December 31, 2019 | 91.76M |
| September 30, 2019 | 245.35M |
| June 30, 2019 | 260.05M |
| March 31, 2019 | 260.05M |
| December 31, 2018 | 248.89M |
| September 30, 2018 | 239.74M |
| June 30, 2018 | 254.92M |
| March 31, 2018 | 265.06M |
| December 31, 2017 | 208.37M |
| September 30, 2017 | 72.39M |
| June 30, 2017 | 58.16M |
| March 31, 2017 | -58.50M |
| December 31, 2016 | -32.48M |
| September 30, 2016 | -11.99M |
| June 30, 2016 | 9.92M |
| March 31, 2016 | 29.47M |
| December 31, 2015 | 43.00M |
| September 30, 2015 | 31.80M |
| June 30, 2015 | 50.23M |
| March 31, 2015 | 37.54M |
| December 31, 2014 | 41.35M |
| September 30, 2014 | 39.94M |
| June 30, 2014 | 55.30M |
| March 31, 2014 | 66.75M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Incyte Corp. | 6.344B |
| Neurocrine Biosciences, Inc. | 3.694B |
| AVITA Medical, Inc. | -27.84M |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.577B |
| Total Liabilities (Quarterly) | 2.434B |
| Debt to Equity Ratio | 14.95 |
| Current Ratio | 2.709 |
| Net Debt Paydown Yield | -1.43% |